Reduction of dysbiosis in children treated with proton pump inhibitors

Background and methods

Gastroesophageal reflux (GERD) is a condition when the gastric acid content flows back into the esophagus. Proton pump inhibitors (PPI) has become the first line therapy prescribed for children over one year with GERD. According to some research the use of PPI may be involved in the pathogenesis of small intestinal bacterial overgrowth (SIBO).
In this randomized, single-blind, placebo-controlled study 128 children with GERD were treated with PPI and L. reuteri Protectis (5 drops/day), or PPI and placebo, for 12 weeks. The prevalence of SIBO was determined by glucose hydrogen breath test before and after treatment. As reference, they were also compared to 120 healthy children.

Results

L. reuteri Protectis significantly reduced the prevalence of SIBO in children with GERD treated with PPI. In addition, L. reuteri Protectis also reduced gastrointestinal symptoms in children with SIBO.

Conclusion

L. reuteri Protectis as adjuvant to PPI treatment may reduce the prevalence of SIBO.

How should BioGaia Protectis drops be stored?

BioGaia Protectis drops comes in two different versions, we therefore recommend you to follow the instructions on the package. However, if room temperature is above 25°C/77°F we always recommend storage in the fridge.

Why does BioGaia Protectis drops come in a new delivery system?

In BioGaia we are constantly working on improving our products. The Easydropper is a new delivery system for probiotic products. It has an improved drop function which facilitates the administration of the product​ and less environmental impact compared to glass bottles.

Are multi-strain products better than single-strain probiotic products?

Multi-strain products containing several strains in high doses do not necessarily have a better effect than a single-strain product. Important criteria when choosing a probiotic product are:

• The probiotic bacteria must be defined on strain level

• The probiotic product must have been tested in human clinical studies, with the same dose and with the same bacterial strain(s) as in the commercial product.

What is Lactobacillus reuteri?

Lactobacillus reuteri (L. reuteri) is a probiotic bacteria that has co-evolved with humans since the beginning of time, and because of that it is adapted to its host. L. reuteri is among the first bacterial species to naturally become established in the microbiota of the newborn. BioGaia probiotic products with L. reuteri are among the most scientifically well-documented probiotics in the world with regard to both efficacy and safety. To date 202 clinical studies with BioGaia’s L. reuteri-strains have been performed in more than 17,200 people of all ages. Positive results have been shown for several gastrointestinal disorders and oral health. Results have been published in 180 articles in scientific journals (February 2019).

Read more about Lactobacillus reuteri.

BioGaia Protectis minipack

BioGaia Protectis minipack is a food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis (L. reuteri DSM 17938) that helps the good microorganisms restore a natural balance in the gut. BioGaia Protectis minipack is a probiotic powder that can be used in all cold foods and drinks. The convenient administration ensures that the whole family stays protected against infections regardless if they are sensitive to sweeteners or specific flavors, or if they have difficulties swallowing pills. The powder can either be sprinkled on foods, mixed into drinks or taken directly into the mouth.

Because L. reuteri Protectis naturally colonizes humans it has a strong adaptation to persist and interact with humans. L. reuteri Protectis has been tested in more than 130 clinical trials and proven both effective and safe for children.